Comprehensive HIV and Harm Prevention Via Telehealth

Comprehensive HIV and Harm Prevention Via Telehealth: CHARIOT, a Randomized Controlled Trial

The purpose of this study is to test 2 different ways to offer medications to prevent human immunodeficiency virus (HIV), cure hepatitis C virus (HCV) (if applicable) and treat substance use disorder (if desired) in people who inject drugs.

Inclusion Criteria:

• age 18 or older
• able to speak English or Spanish
• willing and able to sign informed consent, provide locator information and medical records release
• non-reactive result on rapid HIV test
• use of SSP to exchange syringes 2 times in the past 3 months
• planning to stay in the area for 12 months

Exclusion Criteria:

• reactive HIV test
• currently on medications for opioid use disorder (MOUD) by urine drug screen
• currently on PrEP by self-report
• Principal or site investigator discretion
• currently in prison or jail
• current enrollment in Clinical Trials Network 121
• receipt of tele-harm reduction in previous 3 months
• signs or symptoms of acute HIV infection